Search research articles
Contact Us
Filters
Showing results (91-100 of 113) with videos related to
Page
of 12
Sort By:
Indian Journal of Cancer
|
August 11, 2025
Clinical characteristics and outcomes of isolated myeloid sarcoma without bone marrow involvement: An experience from a tertiary cancer care center in India
A H Rudresha, Antony G F Thottian, Sreevalli Anantharamu, et al.
Leukemia & Lymphoma
|
October 13, 2016
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial
Tadeusz Robak, Krzysztof Warzocha, K Govind Babu, et al.
Lancet (London, England)
|
April 18, 2015
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
Peter Hillmen, Tadeusz Robak, Ann Janssens, et al.
The Lancet. Haematology
|
November 29, 2016
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial
Jorge E Cortes, Carmino Antonio De Souza, Manuel Ayala, et al.
International Journal of Cancer
|
November 9, 2021
The clinical utility and safety of short-course immune checkpoint inhibitors in multiple tumours-A real-world multicentric study from India
George Abraham, Vanita Noronha, Senthil Rajappa, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
May 6, 2024
A phase II randomized, double-blind, placebo-controlled study of Nuvastatic (C50SEW505OESA), a standardized rosmarinic acid-rich polymolecular botanical extract formulation to reduce cancer-related fatigue in patients with solid tumors
Mei Ling Ng, Amin Malik Shah Abdul Majid, Siew Mei Yee, et al.
The Lancet. Oncology
|
December 5, 2024
Cancer care and outreach in the South Asian Association for Regional Cooperation (SAARC) region: overcoming barriers and addressing challenges
M Saiful Huq, Sandhya C Acharya, Saugat Poudyal, et al.
Breast Cancer Research and Treatment
|
March 5, 2016
Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study
Minish M Jain, Smita U Gupte, Shekhar G Patil, et al.
Scientific Reports
|
April 11, 2025
Comprehensive genomic profiling reveals a unique genomic landscape in solid tumors in an Indian cancer cohort of 1000 patients: a single institutional experience
Mithua Ghosh, Sheela Mysore Lingaraju, Krishna C R, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2024
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Yen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy Azim, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 113) with videos related to
Sort By:
Page
of 12
Indian Journal of Cancer
|
August 11, 2025
Clinical characteristics and outcomes of isolated myeloid sarcoma without bone marrow involvement: An experience from a tertiary cancer care center in India
A H Rudresha, Antony G F Thottian, Sreevalli Anantharamu, et al.
Leukemia & Lymphoma
|
October 13, 2016
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial
Tadeusz Robak, Krzysztof Warzocha, K Govind Babu, et al.
Lancet (London, England)
|
April 18, 2015
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
Peter Hillmen, Tadeusz Robak, Ann Janssens, et al.
The Lancet. Haematology
|
November 29, 2016
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial
Jorge E Cortes, Carmino Antonio De Souza, Manuel Ayala, et al.
International Journal of Cancer
|
November 9, 2021
The clinical utility and safety of short-course immune checkpoint inhibitors in multiple tumours-A real-world multicentric study from India
George Abraham, Vanita Noronha, Senthil Rajappa, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
May 6, 2024
A phase II randomized, double-blind, placebo-controlled study of Nuvastatic (C50SEW505OESA), a standardized rosmarinic acid-rich polymolecular botanical extract formulation to reduce cancer-related fatigue in patients with solid tumors
Mei Ling Ng, Amin Malik Shah Abdul Majid, Siew Mei Yee, et al.
The Lancet. Oncology
|
December 5, 2024
Cancer care and outreach in the South Asian Association for Regional Cooperation (SAARC) region: overcoming barriers and addressing challenges
M Saiful Huq, Sandhya C Acharya, Saugat Poudyal, et al.
Breast Cancer Research and Treatment
|
March 5, 2016
Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study
Minish M Jain, Smita U Gupte, Shekhar G Patil, et al.
Scientific Reports
|
April 11, 2025
Comprehensive genomic profiling reveals a unique genomic landscape in solid tumors in an Indian cancer cohort of 1000 patients: a single institutional experience
Mithua Ghosh, Sheela Mysore Lingaraju, Krishna C R, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2024
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Yen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy Azim, et al.
Page
of 12